FDA Approves Restricted Use Of Clenbuterol For Horses

On May 11, 1998, the Food and Drug Administration (FDA) approved Ventipulmin (clenbuterol hydrochloride) Syrup for use in horses affected with airway obstruction, such as occurs with Chronic Obstructive Pulmonary Disease (COPD), also known

Share
Favorite
Close

No account yet? Register

ADVERTISEMENT

On May 11, 1998, the Food and Drug Administration (FDA) approved Ventipulmin (clenbuterol hydrochloride) Syrup for use in horses affected with airway obstruction, such as occurs with Chronic Obstructive Pulmonary Disease (COPD), also known as  heaves. There are a large number of horses afflicted with this condition, and many veterinarians, horse owners, and members of horse-related veterinary and owner associations have been eager to see the drug available in the United States for reducing pain and suffering in affected horses.


Ventipulmin Syrup is an orally administered product used to decrease the labor of breathing in horses with obstructive airway disease. The product is available only by prescription. The recommended duration of treatment is 30 days. The most notable side effects are sweating, muscle tremors, hives, restlessness, and increased heart rates. These subside within a few days after the initiation of treatment.


Ventipulmin Syrup contains a small amount of clenbuterol, which belongs to the family of compounds called Beta-agonists. It is well known that clenbuterol affects lung and heart functions. In Europe, human illness was associated with consumption of meat containing clenbuterol residue. The most notable incident occurred in Spain in 1990 and was associated with consumption of liver from animals that had been illegally administered clenbuterol. Symptoms from clenbuterol can include increased heart rate, muscular tremors, headache, dizziness, nausea, fever, and chills. Concerns over the abuse of clenbuterol in food animals in the United States have led to strict enforcement against illegal sales and use. FDA has added clenbuterol to the list of drugs that are prohibited from extra-label use in animals (Code of Federal Regulations, Title 21, Part 530.41), and FDA and USDA both use tests that can monitor for residues at slaughter.


The sponsor of Ventipulmin, Boehringer Ingleheim Animal Health, Inc. (BIAH), of St. Joseph, Mo., is taking several steps to ensure that the approved drug is not misused

Create a free account with TheHorse.com to view this content.

TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.

Start your free account today!

Already have an account?
and continue reading.

Share

Written by:

Product and information releases by various organizations and companies.

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from TheHorse.com

Sponsored Content

Weekly Poll

sponsored by:

When do you begin to prepare/stock up on products/purchase products for these skin issues?
105 votes · 105 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with TheHorse.com!